Published in PLoS One on August 23, 2010
Evolutionary dynamics of cancer in response to targeted combination therapy. Elife (2013) 2.76
Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML. Clin Med Insights Oncol (2011) 0.93
Cancer: calculated treatment. Nature (2013) 0.91
Synergy Maps: exploring compound combinations using network-based visualization. J Cheminform (2015) 0.82
Quantitative modeling of chronic myeloid leukemia: insights from radiobiology. Blood (2012) 0.81
Dynamics of resistance development to imatinib under increasing selection pressure: a combination of mathematical models and in vitro data. PLoS One (2011) 0.79
Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia. Expert Rev Anticancer Ther (2013) 0.78
Optimized Treatment Schedules for Chronic Myeloid Leukemia. PLoS Comput Biol (2016) 0.75
Bioactivity in Rhododendron: A Systemic Analysis of Antimicrobial and Cytotoxic Activities and Their Phylogenetic and Phytochemical Origins. Front Plant Sci (2017) 0.75
Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors. PLoS Comput Biol (2016) 0.75
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med (2006) 13.54
Resistance in the land of molecular cancer therapeutics. Cancer Cell (2002) 12.15
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med (2006) 8.26
Mutation and cancer: a model for human carcinogenesis. J Natl Cancer Inst (1981) 5.59
A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep (1980) 4.66
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood (2007) 4.15
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol (2008) 3.85
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood (2007) 3.59
The biology of CML blast crisis. Blood (2004) 3.59
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature (2010) 3.39
Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol (2003) 3.38
Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol (2007) 3.37
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer (2007) 3.36
Strategies to overcome resistance to targeted protein kinase inhibitors. Nat Rev Drug Discov (2004) 3.25
Drug resistance in cancer: principles of emergence and prevention. Proc Natl Acad Sci U S A (2005) 3.03
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood (2006) 2.50
Imatinib as a paradigm of targeted therapies. Adv Cancer Res (2004) 2.11
Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. J Biol Chem (2008) 2.09
Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol (2004) 1.83
Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood (2006) 1.83
Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood (2006) 1.82
Trends in leukemia incidence and survival in the United States (1973-1998). Cancer (2003) 1.81
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol (2003) 1.75
SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. Proc Natl Acad Sci U S A (2008) 1.71
Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma (2008) 1.63
Crystal structure of the T315I mutant of AbI kinase. Chem Biol Drug Des (2007) 1.60
A stochastic model for the origin and treatment of tumors containing drug-resistant cells. Bull Math Biol (1986) 1.45
Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358. Cancer Res (2007) 1.42
Growth of nonnecrotic tumors in the presence and absence of inhibitors. Math Biosci (1995) 1.40
A stochastic two-stage model for cancer risk assessment. I. The hazard function and the probability of tumor. Risk Anal (1988) 1.36
Stochastic modeling of drug resistance in cancer. J Theor Biol (2005) 1.35
Chronic myelogenous leukemia: mechanisms underlying disease progression. Leukemia (2002) 1.23
Combination of two but not three current targeted drugs can improve therapy of chronic myeloid leukemia. PLoS One (2009) 1.20
Effect of cellular quiescence on the success of targeted CML therapy. PLoS One (2007) 1.18
Evolution of resistance to cancer therapy. Curr Pharm Des (2006) 1.17
Quantitative model for multiple levels of drug resistance in clinical tumors. Cancer Treat Rep (1983) 1.16
Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib. Leuk Lymphoma (2004) 1.15
A mathematical model to study the effects of drug resistance and vasculature on the response of solid tumors to chemotherapy. Math Biosci (2000) 1.14
Chronic myeloid leukemia. Hematology Am Soc Hematol Educ Program (2003) 1.10
Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Leuk Res (2008) 1.06
A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors. Clin Cancer Res (2009) 1.01
Optimizing therapy of chronic myeloid leukemia. Exp Hematol (2007) 0.99
Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease. Int J Hematol (2004) 0.96
Mathematical models of gene amplification with applications to cellular drug resistance and tumorigenicity. Genetics (1990) 0.96
Mutation rates and mechanisms of resistance to etoposide determined from fluctuation analysis. J Natl Cancer Inst (1994) 0.94
Role of mathematical modeling in protocol formulation in cancer chemotherapy. Cancer Treat Rep (1985) 0.93
Inhibitors of ABL and the ABL-T315I mutation. Curr Top Med Chem (2008) 0.93
Overcoming resistance to imatinib by combining targeted agents. Mol Cancer Ther (2003) 0.93
Stochastic modeling of cellular colonies with quiescence: an application to drug resistance in cancer. Theor Popul Biol (2007) 0.91
Chemotherapy for tumors: an analysis of the dynamics and a study of quadratic and linear optimal controls. Math Biosci (2006) 0.91
Danusertib (formerly PHA-739358)--a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor. Recent Results Cancer Res (2010) 0.91
The dynamics of gene amplification described as a multitype compartmental model and as a branching process. Math Biosci (1991) 0.90
A theoretical analysis of interval drug dosing for cell-cycle-phase-specific drugs. Math Biosci (1992) 0.88
New tools for cancer chemotherapy: computational assistance for tailoring treatments. Mol Cancer Ther (2003) 0.88
The application of mathematical modelling to aspects of adjuvant chemotherapy scheduling. J Math Biol (2003) 0.86
Pathogenesis, treatment effects, and resistance dynamics in chronic myeloid leukemia--insights from mathematical model analyses. J Mol Med (Berl) (2007) 0.86
Use of mathematical models for understanding the dynamics of gene amplification. Mutat Res (1993) 0.84
The mathematical modelling of adjuvant chemotherapy scheduling: incorporating the effects of protocol rest phases and pharmacokinetics. Bull Math Biol (2005) 0.81
Genomic instability, tumor heterogeneity and progression. Adv Exp Med Biol (1988) 0.79
Radiogenic leukemia revisited. Blood (1987) 0.79
A two-stage carcinogenesis model for risk assessment. Cell Biol Toxicol (1989) 0.78
Time-continuous branching walk models of unstable gene amplification. Bull Math Biol (1994) 0.77
Antibody neutralization and escape by HIV-1. Nature (2003) 21.48
Computational and evolutionary aspects of language. Nature (2002) 5.39
The role of chromosomal instability in tumor initiation. Proc Natl Acad Sci U S A (2002) 3.46
Evolutionary dynamics of tumor suppressor gene inactivation. Proc Natl Acad Sci U S A (2004) 1.61
Mathematical models of specificity in cell signaling. Biophys J (2007) 1.31
Population genetics of tumor suppressor genes. J Theor Biol (2004) 1.27
Symmetric vs. asymmetric stem cell divisions: an adaptation against cancer? PLoS One (2013) 1.18
Selection in spatial stochastic models of cancer: migration as a key modulator of fitness. Biol Direct (2010) 1.17
Evolutionary dynamics of feedback escape and the development of stem-cell-driven cancers. Proc Natl Acad Sci U S A (2011) 1.14
Early infection and spread of a conditionally replicating adenovirus under conditions of plaque formation. Virology (2011) 1.02
Local regulation of homeostasis favors chromosomal instability. Curr Biol (2003) 1.02
Complex spatial dynamics of oncolytic viruses in vitro: mathematical and experimental approaches. PLoS Comput Biol (2012) 1.02
The worst drug rule revisited: mathematical modeling of cyclic cancer treatments. Bull Math Biol (2010) 1.01
Dependence of the firearm-related homicide rate on gun availability: a mathematical analysis. PLoS One (2013) 0.96
Tumor growth dynamics: insights into evolutionary processes. Trends Ecol Evol (2013) 0.95
Evolutionary models of color categorization. II. Realistic observer models and population heterogeneity. J Opt Soc Am A Opt Image Sci Vis (2009) 0.92
Cancer: calculated treatment. Nature (2013) 0.91
Alzheimer's disease: rapid and slow progression. J R Soc Interface (2011) 0.90
Stochastic modeling of stem-cell dynamics with control. Math Biosci (2012) 0.89
Minimizing the risk of cancer: tissue architecture and cellular replication limits. J R Soc Interface (2013) 0.87
Evolutionary models of color categorization. I. Population categorization systems based on normal and dichromat observers. J Opt Soc Am A Opt Image Sci Vis (2009) 0.86
Emergence and prevention of resistance against small molecule inhibitors. Semin Cancer Biol (2005) 0.85
Cancer-associated mutations in healthy individuals: assessing the risk of carcinogenesis. Cancer Res (2014) 0.85
Stem cell control, oscillations, and tissue regeneration in spatial and non-spatial models. Front Oncol (2013) 0.85
Chromosomal instability and cancer: not just one CINgle mechanism. Gut (2009) 0.82
Specificity and robustness of the mammalian MAPK-IEG network. Biophys J (2009) 0.81
The role of the bi-compartmental stem cell niche in delaying cancer. Phys Biol (2015) 0.80
Signal response sensitivity in the yeast mitogen-activated protein kinase cascade. PLoS One (2010) 0.80
Stochastic control of proliferation and differentiation in stem cell dynamics. J Math Biol (2014) 0.79
Accumulation of neutral mutations in growing cell colonies with competition. J Theor Biol (2012) 0.79
Methylation kinetics and CpG-island methylator phenotype status in colorectal cancer cell lines. Biol Direct (2013) 0.76
On the emergence of multifocal cancers. J Carcinog (2004) 0.75
Nearest-neighbor interactions, habitat fragmentation, and the persistence of host-pathogen systems. Am Nat (2013) 0.75
When learners surpass their models: mathematical modeling of learning from an inconsistent source. Bull Math Biol (2014) 0.75
Quantitative approach for defining basic color terms and color category best exemplars. J Opt Soc Am A Opt Image Sci Vis (2017) 0.75